Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses.
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
High response rate to PD-1 blockade in desmoplastic melanomas
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Treatment of BRAF-mutated advanced cutaneous melanoma.
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
The Role of Alpha-Synuclein in Melanin Synthesis in Melanoma and Dopaminergic Neuronal Cells